LeanLife’s plant-based omega products make everyday foods healthier.
Extracted from flaxseeds, LeanLife delivers high concentration levels of omega-3 as a nutritional additive. Our products are optimally formulated for use in commercial food processing.
VANCOUVER, British Columbia, Feb. 28, 2019 (GLOBE NEWSWIRE) — LeanLife Health Inc. (CSE: LLP) (the “Company”) a Company focused on plant-based food products, is pleased to announce that it has launched a new presentation for its existing shareholders and potential investors.
The presentation provides updated information about LeanLife, including the Company’s recent signing of a Letter of Intent (“LOI”) for testing and production of its products with a local Canadian nutraceutical manufacturing company.
It also includes forward-looking financial projections based on this LOI and further information about recent changes to the company, its products, and its intended market.
The Company also announces that the final number of units for the Company’s oversubscribed private placement as announced on February 8, 2019 is 25,570,000 (amended from 25,370,000) for a new aggregate total of $1,278,500. As well, 25,000 shares are being issued pursuant to an agreement with a consultant.
About LeanLife Health and the Omega-3 Market
LeanLife Health’s products are shelf-stable extractions from flax seed, a plentiful plant-based source of Omega-3, that give them a significant advantage as a fortified food ingredient.
The products can be used as food additives or as nutraceuticals and have been used to make bread, noodles, cheese, yogurt, juice and milk products for the European market.
LeanLife Health’s industry leading Omega-3 product formulations are of the highest quality and contain no cholesterol. Products are available in oil, emulsion and powder forms.
The global Omega-3 market reached USD $33 Billion in 2016 and is expected to reach upwards of USD $57 Billion by 2025, according to a report by Grand View Research, Inc.
For more information, please contact:
Stan Lis, CEO